Tukysa (tucatinib) — United Healthcare

Initial criteria

• Diagnosis of breast cancer
• Disease is advanced unresectable OR metastatic
• Disease is human epidermal growth factor receptor 2 (HER2)-positive
• Patient has been previously treated with an anti-HER2-based regimen in the metastatic setting (e.g., trastuzumab [Kanjinti, Ogivri, Trazimera], pertuzumab [Perjeta], ado-trastuzumab emtansine [Kadcyla])
• Used in combination with trastuzumab (e.g., Kanjinti, Ogivri, Trazimera) AND capecitabine (Xeloda)

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Tukysa therapy

Approval duration

12 months